Heated tobacco products for smoking cessation and reducing smoking prevalence.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
06 01 2022
06 01 2022
Historique:
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Heated tobacco products (HTPs) are designed to heat tobacco to a high enough temperature to release aerosol, without burning it or producing smoke. They differ from e-cigarettes because they heat tobacco leaf/sheet rather than a liquid. Companies who make HTPs claim they produce fewer harmful chemicals than conventional cigarettes. Some people report stopping smoking cigarettes entirely by switching to using HTPs, so clinicians need to know whether they are effective for this purpose and relatively safe. Also, to regulate HTPs appropriately, policymakers should understand their impact on health and on cigarette smoking prevalence. To evaluate the effectiveness and safety of HTPs for smoking cessation and the impact of HTPs on smoking prevalence. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group's Specialised Register, CENTRAL, MEDLINE, and six other databases for relevant records to January 2021, together with reference-checking and contact with study authors and relevant groups. We included randomised controlled trials (RCTs) in which people who smoked cigarettes were randomised to switch to exclusive HTP use or a control condition. Eligible outcomes were smoking cessation, adverse events, and selected biomarkers. RCTs conducted in clinic or in an ambulatory setting were deemed eligible when assessing safety, including those randomising participants to exclusively use HTPs, smoke cigarettes, or attempt abstinence from all tobacco. Time-series studies were also eligible for inclusion if they examined the population-level impact of heated tobacco on smoking prevalence or cigarette sales as an indirect measure. We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking at the longest follow-up point available, adverse events, serious adverse events, and changes in smoking prevalence or cigarette sales. Other outcomes included biomarkers of harm and exposure to toxicants/carcinogens (e.g. NNAL and carboxyhaemoglobin (COHb)). We used a random-effects Mantel-Haenszel model to calculate risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous outcomes, we calculated mean differences on the log-transformed scale (LMD) with 95% CIs. We pooled data across studies using meta-analysis where possible. We included 13 completed studies, of which 11 were RCTs assessing safety (2666 participants) and two were time-series studies. We judged eight RCTs to be at unclear risk of bias and three at high risk. All RCTs were funded by tobacco companies. Median length of follow-up was 13 weeks. No studies reported smoking cessation outcomes. There was insufficient evidence for a difference in risk of adverse events between smokers randomised to switch to heated tobacco or continue smoking cigarettes, limited by imprecision and risk of bias (RR 1.03, 95% CI 0.92 to 1.15; I No studies reported on cigarette smoking cessation, so the effectiveness of heated tobacco for this purpose remains uncertain. There was insufficient evidence for differences in risk of adverse or serious adverse events between people randomised to switch to heated tobacco, smoke cigarettes, or attempt tobacco abstinence in the short-term. There was moderate-certainty evidence that heated tobacco users have lower exposure to toxicants/carcinogens than cigarette smokers and very low- to moderate-certainty evidence of higher exposure than those attempting abstinence from all tobacco. Independently funded research on the effectiveness and safety of HTPs is needed. The rate of decline in cigarette sales accelerated after the introduction of heated tobacco to market in Japan but, as data were observational, it is possible other factors caused these changes. Moreover, falls in cigarette sales may not translate to declining smoking prevalence, and changes in Japan may not generalise elsewhere. To clarify the impact of rising heated tobacco use on smoking prevalence, there is a need for time-series studies that examine this association.
Sections du résumé
BACKGROUND
Heated tobacco products (HTPs) are designed to heat tobacco to a high enough temperature to release aerosol, without burning it or producing smoke. They differ from e-cigarettes because they heat tobacco leaf/sheet rather than a liquid. Companies who make HTPs claim they produce fewer harmful chemicals than conventional cigarettes. Some people report stopping smoking cigarettes entirely by switching to using HTPs, so clinicians need to know whether they are effective for this purpose and relatively safe. Also, to regulate HTPs appropriately, policymakers should understand their impact on health and on cigarette smoking prevalence.
OBJECTIVES
To evaluate the effectiveness and safety of HTPs for smoking cessation and the impact of HTPs on smoking prevalence. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group's Specialised Register, CENTRAL, MEDLINE, and six other databases for relevant records to January 2021, together with reference-checking and contact with study authors and relevant groups.
SELECTION CRITERIA
We included randomised controlled trials (RCTs) in which people who smoked cigarettes were randomised to switch to exclusive HTP use or a control condition. Eligible outcomes were smoking cessation, adverse events, and selected biomarkers. RCTs conducted in clinic or in an ambulatory setting were deemed eligible when assessing safety, including those randomising participants to exclusively use HTPs, smoke cigarettes, or attempt abstinence from all tobacco. Time-series studies were also eligible for inclusion if they examined the population-level impact of heated tobacco on smoking prevalence or cigarette sales as an indirect measure.
DATA COLLECTION AND ANALYSIS
We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking at the longest follow-up point available, adverse events, serious adverse events, and changes in smoking prevalence or cigarette sales. Other outcomes included biomarkers of harm and exposure to toxicants/carcinogens (e.g. NNAL and carboxyhaemoglobin (COHb)). We used a random-effects Mantel-Haenszel model to calculate risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous outcomes, we calculated mean differences on the log-transformed scale (LMD) with 95% CIs. We pooled data across studies using meta-analysis where possible.
MAIN RESULTS
We included 13 completed studies, of which 11 were RCTs assessing safety (2666 participants) and two were time-series studies. We judged eight RCTs to be at unclear risk of bias and three at high risk. All RCTs were funded by tobacco companies. Median length of follow-up was 13 weeks. No studies reported smoking cessation outcomes. There was insufficient evidence for a difference in risk of adverse events between smokers randomised to switch to heated tobacco or continue smoking cigarettes, limited by imprecision and risk of bias (RR 1.03, 95% CI 0.92 to 1.15; I
AUTHORS' CONCLUSIONS
No studies reported on cigarette smoking cessation, so the effectiveness of heated tobacco for this purpose remains uncertain. There was insufficient evidence for differences in risk of adverse or serious adverse events between people randomised to switch to heated tobacco, smoke cigarettes, or attempt tobacco abstinence in the short-term. There was moderate-certainty evidence that heated tobacco users have lower exposure to toxicants/carcinogens than cigarette smokers and very low- to moderate-certainty evidence of higher exposure than those attempting abstinence from all tobacco. Independently funded research on the effectiveness and safety of HTPs is needed. The rate of decline in cigarette sales accelerated after the introduction of heated tobacco to market in Japan but, as data were observational, it is possible other factors caused these changes. Moreover, falls in cigarette sales may not translate to declining smoking prevalence, and changes in Japan may not generalise elsewhere. To clarify the impact of rising heated tobacco use on smoking prevalence, there is a need for time-series studies that examine this association.
Identifiants
pubmed: 34988969
doi: 10.1002/14651858.CD013790.pub2
pmc: PMC8733777
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD013790Informations de copyright
Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Références
J Epidemiol. 2022 Mar 5;32(3):139-144
pubmed: 33456019
Atherosclerosis. 2005 Mar;179(1):177-83
pubmed: 15721025
Medicina (Kaunas). 2020 Jun 12;56(6):
pubmed: 32545573
Tob Control. 2008 Aug;17(4):222-9
pubmed: 18332064
Regul Toxicol Pharmacol. 2016 Nov 30;81 Suppl 2:S139-S150
pubmed: 27816672
Nicotine Tob Res. 2019 Aug 19;21(9):1220-1227
pubmed: 29912406
Intern Emerg Med. 2021 Nov;16(8):2201-2212
pubmed: 34196886
Tob Control. 2018 Nov;27(Suppl 1):s9-s12
pubmed: 30131374
Contemp Clin Trials Commun. 2020 Jan 08;17:100518
pubmed: 31956726
Psychopharmacology (Berl). 2006 Mar;184(3-4):274-85
pubmed: 16362402
Nicotine Tob Res. 2018 Jan 5;20(2):173-182
pubmed: 28177498
Addiction. 2020 Jun;115(6):1141-1148
pubmed: 31994254
JAMA. 2014 Jan 8;311(2):164-71
pubmed: 24399555
Psychol Health. 2017 Aug;32(8):1018-1036
pubmed: 28553727
Int J Health Sci (Qassim). 2016 Jul;10(3):425-35
pubmed: 27610066
Int J Environ Res Public Health. 2020 May 20;17(10):
pubmed: 32443663
Addiction. 2012 Jan;107(1):197-205
pubmed: 21883605
Cochrane Database Syst Rev. 2022 Jan 6;1:CD013790
pubmed: 34988969
Biomarkers. 2015;20(6-7):382-90
pubmed: 26525849
Cochrane Database Syst Rev. 2016 May 09;(5):CD006103
pubmed: 27158893
Nicotine Tob Res. 2018 Jan 5;20(2):161-172
pubmed: 28177489
Int J Occup Med Environ Health. 2019 Oct 16;32(5):595-634
pubmed: 31584041
Lancet Reg Health Eur. 2021 Jul 14;8:100159
pubmed: 34557853
Psychopharmacology (Berl). 1998 Oct;139(3):288-90
pubmed: 9784088
N Engl J Med. 2017 Oct 5;377(14):1391-1398
pubmed: 28976864
Regul Toxicol Pharmacol. 2012 Nov 1;64(2 Suppl):S54-63
pubmed: 22940437
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538
pubmed: 23193840
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302
pubmed: 28151705
BMC Public Health. 2017 Aug 22;17(1):673
pubmed: 28830420
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3421-5
pubmed: 19959691
Cochrane Database Syst Rev. 2018 May 31;5:CD000146
pubmed: 29852054
Regul Toxicol Pharmacol. 2012 Nov 1;64(2 Suppl):S74-84
pubmed: 22951349
Ann Intern Med. 2017 Mar 21;166(6):390-400
pubmed: 28166548
Toxicol Lett. 2020 May 5;330:30-40
pubmed: 32380119
Food Chem Toxicol. 2017 Aug;106(Pt A):522-532
pubmed: 28576286
Toxicol Sci. 2016 Jun;151(2):347-64
pubmed: 26969371
JMIR Res Protoc. 2018 Aug 24;7(8):e11294
pubmed: 30143474
Tob Control. 2019 Mar;28(2):237-238
pubmed: 29724866
Regul Toxicol Pharmacol. 2018 Jul;96:127-134
pubmed: 29738810
Annu Rev Pharmacol Toxicol. 2009;49:57-71
pubmed: 18834313
N Engl J Med. 2010 Jun 17;362(24):2295-303
pubmed: 20554984
Int J Environ Res Public Health. 2021 Jun 21;18(12):
pubmed: 34205612
Regul Toxicol Pharmacol. 2012 Nov 1;64(2 Suppl):S35-44
pubmed: 22940436
Korean J Fam Med. 2020 Sep;41(5):273-281
pubmed: 32961046
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
BMJ. 2019 Sep 19;366:l5649
pubmed: 31537546
Sci Rep. 2021 Jun 24;11(1):13203
pubmed: 34168216
Tob Control. 2018 Nov;27(Suppl 1):s20-s25
pubmed: 30158203
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Addiction. 2004 Jan;99(1):29-38
pubmed: 14678060
Tob Control. 2020 Jan;29(1):89-95
pubmed: 30696783
Cochrane Database Syst Rev. 2019 Jun 05;6:CD009670
pubmed: 31166007
Eur J Prev Cardiol. 2021 Sep 20;28(11):e9-e11
pubmed: 32340460
Nicotine Tob Res. 2020 Apr 17;22(4):549-559
pubmed: 31125079
Tob Control. 2017 Mar;26(e1):e23-e28
pubmed: 27729564
Nicotine Tob Res. 2020 Apr 17;22(4):539-548
pubmed: 30722062
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054
Cochrane Database Syst Rev. 2021 Jan 4;1:CD013229
pubmed: 33411338
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Nicotine Tob Res. 2021 Feb 16;23(3):584-591
pubmed: 32776101
Drug Alcohol Rev. 2020 Nov;39(7):994-1005
pubmed: 32458503
Vasc Med. 2020 Dec;25(6):572-574
pubmed: 32721197
Tob Control. 2021 Jan;30(1):16-23
pubmed: 31941822
Biomarkers. 2015;20(6-7):404-10
pubmed: 26525962
Tob Control. 2022 Jan;31(1):11-18
pubmed: 32994299
Addiction. 2019 Sep;114(9):1627-1638
pubmed: 31117151
Sci Rep. 2020 Nov 5;10(1):19227
pubmed: 33154508
Tob Control. 2020 Jul;29(4):381-387
pubmed: 31209129
Regul Toxicol Pharmacol. 2016 Nov 30;81 Suppl 2:S151-S157
pubmed: 27845159
Environ Int. 2013 Oct;60:71-80
pubmed: 24013021
Int J Environ Res Public Health. 2018 Dec 18;15(12):
pubmed: 30567400
Biomarkers. 2015;20(6-7):391-403
pubmed: 26554277
Nicotine Tob Res. 2002 Nov;4(4):467-76
pubmed: 12521406
Tob Control. 2019 Sep;28(5):582-594
pubmed: 30181382
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1934-1943
pubmed: 31270101
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2963-8
pubmed: 16365017
Tob Control. 2018 Nov;27(Suppl 1):s102-s110
pubmed: 30305324
Regul Toxicol Pharmacol. 2012 Nov 1;64(2 Suppl):S45-53
pubmed: 22951346
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
Stat Med. 2008 Dec 20;27(29):6072-92
pubmed: 18800342
Addiction. 2019 May;114(5):787-797
pubmed: 30614586
Rapid Commun Mass Spectrom. 2008 Sep;22(17):2629-38
pubmed: 18666198